Company research
Alzamend Neuro, Inc.
CIK 1677077Updated Sep 24, 2026
SecurityALZN · NASDAQ · equity
ALZN price & chart
Loading TradingView…
NASDAQ:ALZN on TradingView ↗About the company
We were incorporated on February 26, 2016, as Alzamend Neuro, Inc. under the laws of the State of Delaware. We were formed to acquire and commercialize patented intellectual property and know-how to prevent, treat and potentially cure the crippling and deadly Alzheimer’s. With our two product candidates, we aim to bring treatment or cures not only for Alzheimer’s, but also bipolar disorder (“BD”), major depressive disorder (“MDD”) and post-traumatic stress disorder (“PTSD”). Existing Alzheimer’s treatments only temporarily relieve symptoms but do not, to our knowledge, slow or halt the underlying worsening of the disease. We have developed a novel approach to combat Alzheimer’s through immunotherapy.
In the news
No coverage from other publishers is available.
Recent filings
Show 5 more recent filings
Financials
FY 2026 · USDSource
Source
Source
Source
Source
balance sheet · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| ASSETS | ||||
| AssetsUSD | 2,079,363Source | 4,602,983Source | 631,588Source | 5,915,625Source |
| Property, Plant and Equipment, NetUSD | 314,866Source | 425,606Source | 176,346Source | 79,843Source |
| Current assets: | ||||
| Cash and Cash Equivalents, at Carrying ValueUSD | 710,689Source | 3,948,658Source | 376,048Source | 5,140,859Source |
| Assets, CurrentUSD | 1,764,497Source | 4,177,377Source | 455,242Source | 5,835,782Source |
| Prepaid Expense and Other Assets, CurrentUSD | 1,053,808Source | 228,719Source | 79,194Source | 447,589Source |
| LIABILITIES AND EQUITY | ||||
| LiabilitiesUSD | 1,346,152Source | 634,761Source | 3,225,773Source | 2,870,122Source |
| Stockholders’ equity: | ||||
| Common Stock, Value, IssuedUSD | 425Source | 78Source | 69Source | 9,694Source |
| Additional Paid in CapitalUSD | 68,040,429Source | 62,503,405Source | 51,426,154Source | 61,991,766Source |
| Retained Earnings (Accumulated Deficit)USD | -67,307,643Source | -58,535,261Source | -54,020,408Source | -44,072,662Source |
| Stockholders' Equity Attributable to ParentUSD | 733,211Source | 3,968,222Source | -2,594,185Source | 3,045,503Source |
| Liabilities and EquityUSD | 2,079,363Source | 4,602,983Source | 631,588Source | 5,915,625Source |
| Current liabilities: | ||||
| Liabilities, CurrentUSD | — | — | — | 2,870,122Source |
| Accounts Payable, CurrentUSD | — | — | 2,925,059Source | 2,870,122Source |
cash flow · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Cash flows from operating activities: | ||||
| Net Income (Loss), Including Portion Attributable to Noncontrolling InterestUSD | 8,800,000Source | 4,500,000Source | 9,900,000Source | 14,900,000Source |
| Adjustments to reconcile net income to net cash provided by operating activities: | ||||
| Share-based Payment Arrangement, Noncash ExpenseUSD | 707,527Source | 325,108Source | 955,633Source | 3,582,625Source |
| Net Cash Provided by (Used in) Operating ActivitiesUSD | -8,067,813Source | -6,568,186Source | -8,269,993Source | -8,923,152Source |
| Cash flows from investing activities: | ||||
| Net Cash Provided by (Used in) Investing ActivitiesUSD | — | -300,000Source | -147,243Source | — |
| Cash flows from financing activities: | ||||
| Net Cash Provided by (Used in) Financing ActivitiesUSD | 4,829,844Source | 10,440,796Source | 3,652,425Source | 200Source |
| Cash, Cash Equivalents, Restricted Cash and Restricted Cash EquivalentsUSD | 710,689Source | 3,948,658Source | 376,048Source | 5,140,859Source |
| Supplemental disclosure of cash flow information: | ||||
| Income Taxes Paid, NetUSD | 1,100Source | — | — | — |
| Additional Financial Items | ||||
| Share-based Payment Arrangement, ExpenseUSD | 707,527Source | 325,108Source | 955,633Source | 3,582,625Source |
| DepreciationUSD | 110,740Source | 50,740Source | 50,740Source | 23,066Source |
| General and Administrative ExpenseUSD | 5,137,056Source | 3,081,896Source | 3,482,538Source | 7,424,609Source |
| Investment Income, InterestUSD | 1,078Source | — | — | — |
| Net Income (Loss) Attributable to ParentUSD | -8,772,382Source | -4,514,853Source | -9,947,746Source | -14,878,167Source |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -8,772,382Source | -5,105,084Source | — | — |
| Nonoperating Income (Expense)USD | -5,541Source | -18,029Source | -10,101Source | -7,701Source |
| Operating ExpensesUSD | 8,766,841Source | 4,496,824Source | 9,937,645Source | — |
| Proceeds from Issuance of Common StockUSD | 794,844Source | 2,704,052Source | 1,252,425Source | — |
| Proceeds from Stock Options ExercisedUSD | — | 600Source | — | 200Source |
income statement · annual statements
| Line item | FY 2026 | FY 2025 | FY 2024 | FY 2023 |
|---|---|---|---|---|
| Operating Income (Loss)USD | -8,766,841Source | -4,496,824Source | -9,937,645Source | -14,870,466Source |
| Income (Loss) from Continuing Operations before Income Taxes, Noncontrolling InterestUSD | -8,771,281Source | -4,514,853Source | -9,947,746Source | -14,878,167Source |
| Net Income (Loss) Attributable to ParentUSD | -8,772,382Source | -4,514,853Source | -9,947,746Source | -14,878,167Source |
| Earnings Per Share, BasicUSD per share | -2.63Source | -11.32Source | -14.7Source | -0.15Source |
| Earnings Per Share, DilutedUSD per share | -2.63Source | -11.32Source | -14.7Source | -0.15Source |
| Weighted Average Number of Shares Outstanding, Basicshares | 3,337,143Source | 450,799Source | 676,565Source | 97,519,016Source |
| Weighted Average Number of Shares Outstanding, Dilutedshares | 3,337,143Source | 450,799Source | 676,565Source | 97,519,016Source |
| Additional Financial Items | ||||
| Costs and ExpensesUSD | — | — | — | 14,870,466Source |
| General and Administrative ExpenseUSD | 5,137,056Source | 3,081,896Source | 3,482,538Source | 7,424,609Source |
| Income (Loss) from Continuing Operations before Income Taxes, DomesticUSD | -8,771,281Source | -4,514,853Source | -9,947,746Source | -14,878,167Source |
| Interest ExpenseUSD | 6,619Source | 18,029Source | 10,101Source | 7,701Source |
| Investment Income, InterestUSD | 1,078Source | — | — | — |
| Net Income (Loss) Available to Common Stockholders, BasicUSD | -8,772,382Source | -5,105,084Source | — | — |
| Nonoperating Income (Expense)USD | -5,541Source | -18,029Source | -10,101Source | -7,701Source |
| Operating ExpensesUSD | 8,766,841Source | 4,496,824Source | 9,937,645Source | — |
| Research and Development ExpenseUSD | 3,629,785Source | 1,414,928Source | 6,455,107Source | 7,445,857Source |